MLAA-34236-244 peptide (ILDRHNFAI) was identified as an effective HLA-A*0201-restricted CTL epitope that inhibited tumor growth and improved survival in leukemia-bearing humanized mice.
ILDRHNFAI9-amino acid peptide epitope from MLAA-34 identified as effective vaccine target for acute monocytic leukemia
What the researchers found
MLAA-34236-244 (ILDRHNFAI) showed strongest HLA-A*0201 binding, induced specific CTL responses, inhibited tumor growth, and improved survival in leukemia-bearing humanized SCID mice with favorable cytokine profiles.
Why it matters
Acute monocytic leukemia has limited targeted therapy options. Identifying a specific peptide vaccine target unique to this cancer type could enable personalized immunotherapy for a disease with poor prognosis.
The numbers in context
10 epitopes predicted; 3 (positions 324-332, 293-301, 236-244) strongly activated CTLs and killed leukemia cells.
How the study worked
Bioinformatic epitope prediction from MLAA-34 protein. HLA-A*0201 binding assays. Tetramer staining. IFN-γ ELISPOT. Cytotoxicity assays against THP-1 cells. In vivo vaccine testing in humanized SCID mice. CD8+ vs CD4+ T cell killing comparison.
Who was studied
HLA-A*0201-restricted MLAA-34 epitopes tested against M5 leukemia cells in vitro
What this study cannot tell us
HLA-A*0201 restriction limits applicability to patients with this allele. Humanized SCID mouse model doesn't fully recapitulate human immune responses. Translation from mouse model to clinical leukemia treatment requires human trials.
How to read the evidence
Comprehensive preclinical evidence from epitope prediction through in vivo vaccine efficacy with mechanistic validation. HLA restriction limits generalizability.
When this study was published
Published in 2021. Peptide-based leukemia vaccines continue to be developed with expanding HLA coverage.
The bigger picture
Peptide-based cancer vaccines targeting leukemia-specific antigens could provide gentler alternatives to the intense chemotherapy and bone marrow transplants currently used for acute leukemia. MLAA-34's unique expression pattern makes it an ideal target.
Questions still open
- Can MLAA-34236-244 peptide vaccine be advanced to clinical trials for M5 leukemia patients?
- Would combining this peptide vaccine with checkpoint inhibitors enhance anti-leukemic responses?
- Could other MLAA-34 epitopes cover additional HLA types for broader patient applicability?
Common questions
What is acute monocytic leukemia?
How does a peptide vaccine fight leukemia?
Read the original research
Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
Journal of immunotherapy (Hagerstown, Md. : 1997), 44(4), 141-150
Citation
Bai, Ju; Wang, Jianli; Yang, Yun; Wang, Fangxia; He, Aili; Zhang, Wanggang. (2021). Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.. Journal of immunotherapy (Hagerstown, Md. : 1997), 44(4), 141-150. https://doi.org/10.1097/CJI.0000000000000350